Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.

Autor:	Sturgill EG; Sarah Cannon Research Institute, Nashville, TN., Misch A; Sarah Cannon Research Institute, Nashville, TN.; Genospace, Boston, MA., Lachs R; Sarah Cannon Research Institute, Nashville, TN.; Genospace, Boston, MA., Jones CC; Sarah Cannon Research Institute, Nashville, TN., Schlauch D; Sarah Cannon Research Institute, Nashville, TN.; Genospace, Boston, MA., Jones SF; Sarah Cannon Research Institute, Nashville, TN., Shastry M; Sarah Cannon Research Institute, Nashville, TN., Yardley DA; Sarah Cannon Research Institute, Nashville, TN.; Tennessee Oncology, Nashville, TN., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, TN.; Tennessee Oncology, Nashville, TN., Spigel DR; Sarah Cannon Research Institute, Nashville, TN.; Tennessee Oncology, Nashville, TN., Hamilton EP; Sarah Cannon Research Institute, Nashville, TN.; Tennessee Oncology, Nashville, TN., McKenzie AJ; Sarah Cannon Research Institute, Nashville, TN.
Jazyk:	angličtina
Zdroj:	JCO precision oncology [JCO Precis Oncol] 2021 Nov; Vol. 5, pp. 1297-1311.
DOI:	10.1200/PO.20.00469
Abstrakt:	Purpose: Molecular biomarkers informing disease diagnosis, prognosis, and treatment decisions in patients with breast cancer are being uncovered by next-generation sequencing (NGS) technologies. In this study, we survey how NGS is used for patients with breast cancer in real-world settings with a focus on physician behaviors and sequencing results. Methods: We conducted a retrospective analysis of patients with breast cancer who received NGS testing from commercial vendors as part of standard of care from 2014 to 2019. A total of 2,635 NGS reports from 2,316 unique breast cancer patients were assessed. Hormone receptor and human epidermal growth factor receptor 2 statuses were abstracted from patient medical records. Comparative gene amplification and mutation frequencies were analyzed using Pearson's correlation and Lin's concordance statistics. Results: The number of physicians ordering NGS tests for patients with breast cancer increased more than six-fold from 2014 to 2019. Tissue- and plasma-based tests were ordered roughly equally by 2019, with plasma-based testing ordered most frequently in hormone receptor-positive subtypes. Patients with triple-negative breast cancer were most likely to receive NGS testing. Gene amplifications including ERBB2 were detected less frequently in our real-world data set as compared to previous genomic landscape studies, whereas the opposite was true for gene mutations including ESR1 . Pathogenic mutations in the PI3K pathway (38.6%) and DNA damage repair pathway (11.0%) were frequently reported. Alterations were also reported across other cellular pathways. Conclusion: Overall, we found that an increasing number of physicians in community settings are adopting NGS in the care of patients with breast cancer. Discrepancies between our real-world NGS data and previous genomic landscape studies are likely owed to the prevalence of plasma-based testing in community oncology clinics, as the reference data were from tissue-based NGS alone. Competing Interests: Emma G. SturgillEmployment: HCA/Sarah CannonStock and Other Ownership Interests: HCA Healthcare Rebecca LachsEmployment: Sarah Cannon Research InstituteTravel, Accommodations, Expenses: Sarah Cannon Research Institute Carissa C. JonesEmployment: HCA/Sarah Cannon Dan SchlauchEmployment: Sarah Cannon Research InstituteStock and Other Ownership Interests: HCA Healthcare Suzanne F. JonesEmployment: HCA/Sarah CannonStock and Other Ownership Interests: HCA HealthcareConsulting or Advisory Role: Amgen Mythili ShastryEmployment: Sarah Cannon Research Institute Denise A. YardleyConsulting or Advisory Role: Novartis, Biotheranostics, Bristol Myers Squibb, G1 Therapeutics, Athenex, Immunomedics, Sanofi/Aventis, R-Pharm, LillySpeakers' Bureau: Novartis, Genentech/RocheResearch Funding: Genentech/Roche, Novartis, MedImmune, Lilly, Medivation, Pfizer, Tesaro, Macrogenics, AbbVie, Merck, Clovis Oncology, Amgen, Biomarin, Biothera, Dana Farber Cancer Hospital, Incyte, Innocrin Pharma, Nektar, NSABP Foundation, Odonate Therapeutics, PolyphorTravel, Accommodations, Expenses: Novartis, Genentech/Roche Howard A. Burris IIIEmployment: HCA HealthcareLeadership: HCA HealthcareStock and Other Ownership Interests: HCA HealthcareConsulting or Advisory Role: AstraZeneca, FORMA Therapeutics, Celgene, Incyte, NovartisResearch Funding: Roche/Genentech, Bristol Myers Squibb, Incyte, AstraZeneca, MedImmune, Macrogenics, Novartis, Boehringer Ingelheim, Lilly, Seattle Genetics, Merck, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, BioMed Valley Discoveries, TG Therapeutics, Vertex, eFFECTOR Therapeutics, Janssen, Gilead Sciences, BioAtla, CicloMed, Harpoon therapeutics, Archer, Arvinas, Revolution Medicines, Array BioPharma, Bayer, BIND Therapeutics, Kymab, miRNA Therapeutics, Pfizer, Takeda/Millennium, Foundation Medicine, EMD SeronoExpert Testimony: NovartisUncompensated Relationships: Daiichi Sankyo, Pfizer, Bayer, GRAIL, Novartis, Vincerx PharmaOpen Payments Link: https://openpaymentsdata.cms.gov/physician/201030/summary David R. SpigelLeadership: ASCOConsulting or Advisory Role: Genentech/Roche, Novartis, Celgene, Bristol Myers Squibb, AstraZeneca, Pfizer, GlaxoSmithKline, Merck, Nektar, Takeda, TRM Oncology, Evelo Therapeutics, Illumina, PharmaMar, Aptitude Health, Bayer, Dracen, EMD Serono, Iksuda Therapeutics, Molecular Templates, Seattle Genetics, TRIPTYCH Health Partners, Amgen, Curio Science, Intellisphere, Ipsen, Jazz Pharmaceuticals, Mirati Therapeutics, Puma Biotechnology, Sanofi/Aventis, Exelixis, Novocure, RegeneronResearch Funding: Genentech/Roche, Novartis, Celgene, Bristol Myers Squibb, Lilly, AstraZeneca, University of Texas Southwestern Medical Center—Simmons Cancer Center, Merck, G1 Therapeutics, Neon Therapeutics, Takeda, Nektar, Celldex, Clovis Oncology, Daiichi Sankyo, EMD Serono, Astellas Pharma, GRAIL, Transgene, Aeglea Biotherapeutics, Ipsen, BIND Therapeutics, Eisai, ImClone Systems, Immunogen, Janssen Oncology, MedImmune, Molecular Partners, Agios, GlaxoSmithKline, Tesaro, Cyteir, Apollomics, Novocure, Elevation Oncology, Calithera BiosciencesTravel, Accommodations, Expenses: AstraZeneca, Genentech, Novartis Erika P. HamiltonConsulting or Advisory Role: Pfizer, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond Therapeutics, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Seattle Genetics, Eisai, Deciphera, ArvinasResearch Funding: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Sutro Biopharma, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon Pharmaceuticals, Black Diamond Therapeutics, Orinove, Molecular Templates, Silverback Therapeutics, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics, Shattuck Labs, Merck, PharmaMar, Olema Pharmaceuticals, Polyphor, Immunogen, Plexxikon, Amgen, AkesobioNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu